In the meantime, molecules derived from Omomyc or others that phenocopy its mechanism(s) of action are being—and will be—developed by us and others, increasing our chances of success in the ultimate goal: Developing the first clinically-approved Myc inhibitor, an urgent need for cancer patients. Here, MYC is linked to cancer.